Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,135.00 price target on Eli Lilly (NYSE: LLY)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Novo shares rise for second day after Lilly obesity pills trails Wegovy in trialAugust 8, 2025 6:06 AM Eli Lilly & Co. (LLY) options active on 358K contracts as share price pullbackAugust 8, 2025 5:35 AM Eli Lilly (LLY) PT Lowered to $905 at JefferiesAugust 8, 2025 5:35 AM Form 10-Q ELI LILLY & Co For: Jun 30August 7, 2025 10:00 AM Leerink Partners Downgrades Eli Lilly (LLY) to Market Perform, 'we no longer expect upward pressure on long-term consensus expectations'August 7, 2025 9:20 AM Eli Lilly shares slip 7% premarket as weight-loss pill study overshadows earningsAugust 7, 2025 9:11 AM BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)August 7, 2025 8:28 AM Novo Nordisk shares jump as Eli Lilly obesity pill disappointsAugust 7, 2025 7:54 AM Form 8-K ELI LILLY & Co For: Aug 07August 7, 2025 7:06 AM Lilly raises full-year earnings forecasts on surging demand for weight-loss drugAugust 7, 2025 6:52 AM Eli Lilly & Co. (LLY) Tops Q2 EPS by 72c; lifts guidanceAugust 7, 2025 6:46 AM Lilly reports second-quarter 2025 financial results and raises guidanceAugust 7, 2025 6:45 AM Lilly's oral obesity drug shows 27-pound weight loss in phase 3 trialAugust 7, 2025 6:25 AM Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesityAugust 7, 2025 6:25 AM Stocks expected to have increasing option volume: LLY BDX DDOG WBD QSR PODD RL ZBH H CELH ELAN CROX YETI WRBY PTON August 7, 2025 4:31 AM Eli Lilly Q2 earnings preview: analysts eye obesity drug sales momentumAugust 7, 2025 2:00 AM